Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers

NCT07392411 | Recruiting DMC

• 1 other identifier: 7232048
• Study Type: observational
• Target: 720
• Locations: 1 country
• Sites: 1

Brief Summary

This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.

Conditions

Parkinson's Disease; Progressive Supranuclear Palsy(PSP); Multiple System Atrophy; Healthy Control

Outcome Measures

Primary Outcomes (1)

• Diagnostic Accuracy of the AI Model in Assessing [ Disease/Condition ] Severity

  The effectiveness of the model was demonstrated through a comparison between model-predicted scores and human expert ratings.

  Baseline

Study Arms (4)

Parkinson's disease (PD) group

Participants meeting the 2015 MDS clinical diagnostic criteria for PD, aged 18-75. Includes both early (Hoehn-Yahr stage 1-2.5) and advanced (Hoehn-Yahr stage 2.5-5) patients. All participants provide informed consent for facial video and speech audio data collection. Exclusion criteria: history of stroke, head trauma, hydrocephalus, brain tumors, intracranial surgery, metal implants, pacemakers, severe dyskinesia, or MMSE score ≤ 24.

Other: video recording

Multiple System Atrophy (MSA) Group

Participants diagnosed with MSA-P according to the 2017 Chinese expert consensus diagnostic criteria, aged 18-75. For unified motor assessment, MDS-UPDRS I-IV and Hoehn-Yahr staging are used. All provide informed consent for data collection. Exclusion criteria: history of stroke, head trauma, hydrocephalus, brain tumors, intracranial surgery, metal implants, pacemakers, or MMSE score ≤ 24.

Other: video recording

Progressive Supranuclear Palsy (PSP) Group

Participants diagnosed with PSP according to the 2016 Chinese clinical diagnostic criteria, aged 18-75. For unified motor assessment, MDS-UPDRS I-IV and Hoehn-Yahr staging are used. All provide informed consent for data collection. Exclusion criteria: history of stroke, head trauma, hydrocephalus, brain tumors, intracranial surgery, metal implants, pacemakers, or MMSE score ≤ 24.

Other: video recording

Healthy Control Group

Age- and sex-matched healthy volunteers with no neurological diseases. MMSE score ≥ 24. All participants provide informed consent and undergo the same standardized facial video and speech audio recording tasks as the patient groups. Exclusion criteria: history of any neurological or psychiatric disorders.

Other: video recording

Interventions

video recording OTHER

The patient's facial expressions and speech characteristics were recorded via video for assessment purposes.

Healthy Control Group; Multiple System Atrophy (MSA) Group; Parkinson's disease (PD) group; Progressive Supranuclear Palsy (PSP) Group

Eligibility Criteria

• Age: 15 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

In this study, participants were recruited from a single center in China. They were enrolled through outpatient assessment and screening.

You may not qualify if:

• History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery.
• Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients).
• Severe dyskinesia in PD patients that would compromise cooperation with video/audio recording.
• Mini-Mental State Examination (MMSE) score ≤ 24 points.

Sponsors & Collaborators

• Beijing Tiantan Hospital: lead

Study Sites (1)

首都医科大学附属北京天坛医院

Beijing, Beijing Municipality, 100070, China

RECRUITING

MeSH Terms

Conditions

Parkinson Disease; Supranuclear Palsy, Progressive; Multiple System Atrophy

Interventions

Videotape Recording

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Ophthalmoplegia; Ocular Motility Disorders; Cranial Nerve Diseases; Tauopathies; Paralysis; Neurologic Manifestations; Eye Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Primary Dysautonomias; Autonomic Nervous System Diseases

Intervention Hierarchy (Ancestors)

Tape Recording; Audiovisual Aids; Educational Technology; Technology; Technology, Industry, and Agriculture; Television

Central Study Contacts

Lingyan Ma, M.D.

CONTACT

+8613520873987; Jennifer_MLY@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 30, 2026
• First Posted: February 6, 2026
• Study Start: July 25, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: February 6, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE

Locations

CN (1)